Healthcare of Ontario Pension Plan Trust Fund Buys 80,410 Shares of DexCom, Inc. $DXCM

Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 38.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 289,945 shares of the medical device company’s stock after acquiring an additional 80,410 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in DexCom were worth $19,244,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the last quarter. MCF Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter valued at $32,000. ORG Partners LLC boosted its position in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares during the last quarter. Spire Wealth Management boosted its position in shares of DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after buying an additional 305 shares during the last quarter. Finally, Aventura Private Wealth LLC purchased a new stake in shares of DexCom during the fourth quarter valued at $43,000. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. The trade was a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 40,994 shares of company stock valued at $2,919,022. Company insiders own 0.28% of the company’s stock.

DexCom Trading Down 1.5%

Shares of NASDAQ:DXCM opened at $74.22 on Tuesday. The stock has a market capitalization of $28.64 billion, a price-to-earnings ratio of 31.72, a PEG ratio of 1.18 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock’s 50-day simple moving average is $66.37 and its two-hundred day simple moving average is $67.68. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period last year, the firm posted $0.32 earnings per share. Analysts expect that DexCom, Inc. will post 2.58 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Truist Financial reaffirmed a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Citigroup reaffirmed a “buy” rating and set a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. William Blair raised DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $91.00 price objective on shares of DexCom in a research report on Monday, June 8th. Finally, Mizuho set a $85.00 price objective on DexCom and gave the company an “outperform” rating in a research report on Tuesday, June 9th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.83.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.